880813-42-3

Basic information

• Product Name: CMP5
• CAS NO: 880813-42-3
• Molecular Weight: 315.418
• Mol File: 880813-42-3.mol

Chemical Properties

• CAS DataBase Reference: CMP5(CAS DataBase Reference)
• NIST Chemistry Reference: CMP5(880813-42-3)
• EPA Substance Registry System: CMP5(880813-42-3)

Safety Data

• Hazardous Substances Data: 880813-42-3(Hazardous Substances Data)

Upstream product

• 3731-51-9 2-(Aminomethyl)pyridine 
• 7570-45-8 N-ethyl-3-carbazolealdehyde 
• 86-28-2 N-ethylcarbazole 
• 86-74-8 9H-carbazole 

Relevant articles and documents

Interaction assessments of the first S-adenosylmethionine competitive inhibitor and the essential interacting partner methylosome protein 50 with protein arginine methyltransferase 5 by combined computational methods

Protein arginine methyltransferase 5 (PRMT5) is the most promising anticancer target in PRMT family. In this study, based on the first S-adenosylmethionine (SAM) competitive small molecule inhibitor (17, compound number is from original paper) of PRMT5 reported in our recent paper, we determined the molecular mechanism of 17 interacting with PRMT5 by computational methods. Previously reported CMP5 was also thought of as a SAM competitive inhibitor of PRMT5, but the direct inhibition activity against PRMT5 at enzymatic level was not provided. Therefore, we tested the half-maximal inhibitory concentration (IC50) of CMP5 against PRMT5 at enzymatic level for the purpose of summarizing the interaction characteristics of SAM binding site inhibitors with PRMT5. Additionally, as the essential interacting partner of PRMT5, the binding attributes of the WD-repeat-containing protein MEP50 (methylosome protein 50) was investigated, and nine key residues that contribute most to PRMT5:MEP50 interaction were identified. These results could be helpful in discovering new potent and specific inhibitors of PRMT5, as well as in designing mutant residue assay to modulate the catalytic activity of PRMT5.

Substituted Carbazoles-A New Class of Anthelmintic Agent

A series of novel carbazoles were synthesized based on structural modifications to lead carbazole 1 (EC100≤2.5M against Haemonchus contortus in vitro), which was revealed in a small molecule screening program as a potentially promising platform for the development of new anthelmintic drugs. Subsequently, analogues 19, 21, 41, 42 (EC100≤ 1.25M, all), and 39 (EC100≤0.625M) were demonstrated to exhibit enhanced in vitro anthelmintic activity over the lead structure, with compound 39 also being shown to be active in vivo against Heligmosomoides polygyrus.